Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00966693 · OUTCOME

Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
After one 28-day cycle

What was measured

To determine the dose limitations toxicities of the combination of lenalidomide and thalidomide and dexamethasone (LTD) in patients with relapsed/refractory multiple myeloma (RRMM).

Groups in this outcome

RTD (Cohort 1, Phase 1)

Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 2, Phase 1)

Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 3, Phase 1)

Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle

RTD (Cohort 2, Phase 2)

Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RTD (Cohort 1, Phase 1)3
RTD (Cohort 2, Phase 1)3
RTD (Cohort 3, Phase 1)9
RTD (Cohort 2, Phase 2)49

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
RTD (Cohort 1, Phase 1)1Not reportedNot reportedNot reportedNot reported
RTD (Cohort 2, Phase 1)0Not reportedNot reportedNot reportedNot reported
RTD (Cohort 3, Phase 1)3Not reportedNot reportedNot reportedNot reported
RTD (Cohort 2, Phase 2)0Not reportedNot reportedNot reportedNot reported
Complete source fields
calculate Pct
false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      9
    4. group Id
      OG003
      value
      49
    units
    Participants
description
To determine the dose limitations toxicities of the combination of lenalidomide and thalidomide and dexamethasone (LTD) in patients with relapsed/refractory multiple myeloma (RRMM).
groups
  1. description
    Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG000
    title
    RTD (Cohort 1, Phase 1)
  2. description
    Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG001
    title
    RTD (Cohort 2, Phase 1)
  3. description
    Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG002
    title
    RTD (Cohort 3, Phase 1)
  4. description
    Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \*21 days+ 7 days rest and reevaluation=28 day cycle
    id
    OG003
    title
    RTD (Cohort 2, Phase 2)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
After one 28-day cycle
title
Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice